Navigation Links
The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
Date:5/4/2009

LONDON, May 4 /PRNewswire/ -- The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the Global Active Pharmaceutical Ingredients (API) Market to be held on Wednesday, 6th May 2009, at 3 p.m. GMT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The API market, traditionally dominated by small molecule drugs, is currently witnessing a rapid shift towards biopharmaceuticals. At the same time the manufacturing volume outsourced to contract manufacturing firms is on the rise. As plain vanilla generics continue to get highly competitive, API manufacturers are searching for newer avenues such as the production of high potency API's to differentiate themselves from competition.

Highlights of this briefing include an analysis of the global API market, challenges facing the global API industry, as well as market drivers and restraints, an estimate on the market size, and a look out on emerging trends. The importance of the Asia-Pacific region as an API manufacturing hub will also be covered in this presentation.

This briefing will benefit API manufacturers, contract manufacturing companies, biotechnology as well as pharmaceutical companies, and the financial community wishing to understand the future potential of the API market.

"It is a difficult time for API manufacturers as they continue to battle challenges such as growing competition from low-cost countries and overcapacity. Market participants will increasingly have to rely on strategies such as capability differentiation and consolidation to stay ahead of competition," observes Pharmaceutical & Biotechnology Programme Leader Sumanth Kambhammettu from Frost & Sullivan.

Frost & Sullivan will hold this conference call at 3 p.m. GMT on Wednesday, 6th May 2009, which will provide industry participants an outlook of the Global Active Pharmaceutical Ingredients (API) Market. To participate, please email Katja Feick at katja.feick@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

GIL 2009: Europe

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled.

For more information you can also visit http://www.frost.com/gilglobal

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com/

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: 0049 (0) 69 77 0 33 43
    F: 0049 (0) 69 23 45 66
    E: katja.feick@frost.com
    www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
2. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
3. Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
4. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
5. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
6. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
7. DuPont Leader: Agriculture is Up to Global Productivity Challenge
8. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
9. Global Aviation Summit Explores Low-Carbon Flight
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):